Redhill Biopharma (RDHL) Competitors $2.09 -0.01 (-0.67%) Closing price 02:29 PM EasternExtended Trading$2.08 0.00 (-0.05%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDHL vs. CARM, MRKR, CTXR, RVPH, PMN, GOVX, PRPH, ALLR, HOTH, and LEXXShould you be buying Redhill Biopharma stock or one of its competitors? The main competitors of Redhill Biopharma include Carisma Therapeutics (CARM), Marker Therapeutics (MRKR), Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), Promis Neurosciences (PMN), GeoVax Labs (GOVX), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), Hoth Therapeutics (HOTH), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Redhill Biopharma vs. Its Competitors Carisma Therapeutics Marker Therapeutics Citius Pharmaceuticals Reviva Pharmaceuticals Promis Neurosciences GeoVax Labs ProPhase Labs Allarity Therapeutics Hoth Therapeutics Lexaria Bioscience Carisma Therapeutics (NASDAQ:CARM) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership. Is CARM or RDHL more profitable? Redhill Biopharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -137.38% Redhill Biopharma N/A N/A N/A Do analysts recommend CARM or RDHL? Carisma Therapeutics currently has a consensus price target of $1.93, indicating a potential upside of 383.67%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Carisma Therapeutics is more favorable than Redhill Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43Redhill Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in CARM or RDHL? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 12.6% of Carisma Therapeutics shares are held by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, CARM or RDHL? Carisma Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Redhill Biopharma has a beta of 4.22, meaning that its stock price is 322% more volatile than the S&P 500. Which has preferable valuation & earnings, CARM or RDHL? Redhill Biopharma has lower revenue, but higher earnings than Carisma Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.85-$60.48M-$1.56-0.26Redhill Biopharma$8.04M0.60-$8.27MN/AN/A Does the media favor CARM or RDHL? In the previous week, Carisma Therapeutics had 3 more articles in the media than Redhill Biopharma. MarketBeat recorded 3 mentions for Carisma Therapeutics and 0 mentions for Redhill Biopharma. Carisma Therapeutics' average media sentiment score of 0.22 beat Redhill Biopharma's score of 0.00 indicating that Carisma Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Carisma Therapeutics Neutral Redhill Biopharma Neutral SummaryCarisma Therapeutics beats Redhill Biopharma on 10 of the 14 factors compared between the two stocks. Get Redhill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedhill BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.81M$2.39B$5.51B$8.96BDividend YieldN/A1.80%5.25%4.02%P/E RatioN/A9.2628.0520.16Price / Sales0.60771.14438.35127.91Price / CashN/A161.3437.0657.97Price / Book-0.574.638.125.62Net Income-$8.27M$31.26M$3.16B$248.50M7 Day Performance4.30%6.81%4.40%5.54%1 Month Performance1.76%4.31%4.09%7.52%1 Year Performance-99.06%3.88%34.53%22.06% Redhill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedhill BiopharmaN/A$2.09-0.7%N/A-99.0%$4.81M$8.04M0.00210CARMCarisma Therapeutics2.3948 of 5 stars$0.39-2.2%$1.93+391.6%-66.2%$16.74M$19.63M-0.2520MRKRMarker Therapeutics3.667 of 5 stars$1.53+4.8%$13.17+760.6%-65.6%$16.52M$6.59M-1.1560Positive NewsCTXRCitius Pharmaceuticals2.4386 of 5 stars$1.59+3.9%$53.00+3,233.3%-87.2%$16.27MN/A0.0020News CoverageHigh Trading VolumeRVPHReviva Pharmaceuticals2.2824 of 5 stars$0.38+12.9%$9.00+2,261.6%-69.4%$16.20MN/A-0.485High Trading VolumePMNPromis Neurosciences3.361 of 5 stars$0.48+0.7%$4.50+830.1%-79.7%$15.70MN/A-9.685Positive NewsGap UpGOVXGeoVax Labs3.3861 of 5 stars$0.87-9.8%$11.10+1,182.2%-77.4%$15.29M$3.95M-0.2410Analyst RevisionGap UpPRPHProPhase LabsN/A$0.39+6.6%N/A-87.1%$15.25M$6.77M-0.31130ALLRAllarity Therapeutics0.9524 of 5 stars$1.01+1.0%N/A-83.6%$15.08MN/A0.0010News CoverageHOTHHoth Therapeutics1.4193 of 5 stars$1.17+3.5%$4.00+241.9%+44.1%$14.93MN/A-1.034LEXXLexaria Bioscience2.8502 of 5 stars$0.87+2.5%$7.00+704.6%-65.9%$14.91M$460K-1.477Upcoming Earnings Related Companies and Tools Related Companies Carisma Therapeutics Competitors Marker Therapeutics Competitors Citius Pharmaceuticals Competitors Reviva Pharmaceuticals Competitors Promis Neurosciences Competitors GeoVax Labs Competitors ProPhase Labs Competitors Allarity Therapeutics Competitors Hoth Therapeutics Competitors Lexaria Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDHL) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
